Unverified claims of 'cures' in traditional medicine raise ethical concerns for researchers and the media. Critically analyse.

In 1976, Japanese researchers reported that a 30-herb formula based on an ancient Chinese text helped 9 of 13 advanced cancer patients. The headline read "Chinese herb medicine cures cancer" [1]. Claims like this raise real ethical concerns. The answer is better evidence, not dismissing traditional knowledge.

Ethical concerns for researchers

• Weak evidence presented as a cure: the study had 13 patients, no control group and a subjective "good progress" endpoint. That is a lead, not proof [1].
• Vulnerable subjects: trials on advanced-stage patients need strict informed consent. They must not replace proven treatment.
• Unknown safety: mixes of many herbs are hard to dose consistently. WHO flags weak pharmacovigilance for TCIM products, so "fewer side effects" may only mean that harm went unrecorded [2].

Ethical concerns for the media

• Hope over accuracy: "cure" headlines can make patients delay surgery or chemotherapy. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 bans such claims for cancer in advertisements, but leaves enforcement to the states [3].
• Weak follow-through: Ayush pharmacovigilance centres can only forward misleading adverts to state licensing authorities [4]. The Ayush Suraksha Portal (2025) came only after Supreme Court directions in WP(C) 645/2022 [5].

The other side

• Classical texts hold real value: Tu Youyou studied traditional Chinese medicine to isolate artemisinin and won the 2015 Nobel Prize [6].
• Critique of rigid RCTs: holistic, individualised systems may need adapted trial designs, such as testing the whole treatment package against usual care.
• Policy momentum: WHO's Global Traditional Medicine Strategy 2025–2034 supports integrating TCIM, but its first objective is strengthening evidence [7]. The problem is unverified claims, not traditional medicine itself.

Way forward

• States should act on flagged adverts within a fixed time, tracked publicly on the Ayush Suraksha dashboard [5].
• Follow the artemisinin path: text, then plant, then compound, then trials under the New Drugs and Clinical Trials Rules, 2019.
• The media should state the sample size and study design.

Unverified cure claims undermine patients' ability to make informed choices and erode public trust. The answer is rigorous testing, not rejection. Adapting trial design without lowering the standard of proof, as WHO's strategy envisages [7], will let traditional medicine safely serve SDG 3 and the right to health under Article 21.